[Audio Gap]
The continued external financial support to advance our exciting programs.
I'll walk you through these developments and illustrate how we're taking the way remains success.
We'll begin with our operational and financial progress.
Our lead program, 797, is an allogeneic unmodified iNKT cell therapy currently advancing in a Phase II trial for second-line gastric cancer and acute respiratory disease syndrome, or ARDS.
gastric a challenging high second-line poor with cancer, and prognosis mortality gastric cancer condition a a On rate.
only median Patients gastric undergoing as survival performance a treatment factors or advanced XX of overall gastroesophageal junction status depending second-line cancer typically such therapy on X to for regimen. months, and have
is evaluated for XXX parallel, In ARDS. also being
with of approximately rate is rapidly This mortality a progressive a and life-threatening condition XX%.
unmet benefit Our to medical both addressing commitment critical needs XXX care. therapeutic these potential respiratory provide the and meaningful in underscores oncology of to
Let a incidence and represents aftermath program its has announcement outcomes. me populations, younger rates. systems critical a been Research respiratory the Advanced of been significant high alarmingly begin This II or $XXX ventilator-free randomized committed with has a million Phase our program This outcomes on health by the burden in to on almost urgency mortality ARDS rapidly failure and COVID-XX in from the days. pandemic. ARDS. underscored globally care this high The is ARDS particularly and survival of most recent and prevalence is BARDA, of progressive which likely as condition form Development to Biomedical growing, address by such has with focused severe given Authority, the exacerbated The
of yet therapeutic X disease third agent this substantial the BARDA This options, and already announced. innovative are program evaluate investment been highlights and the setting. have The challenging X with expected for treatment in monoclonal critical not effective disclosed need is antibodies to which
be ventilator-free that cells These incorporated provide typical in into substantial rate treatment XX% and potential of trial with could play can for XXX indicate ARDS, and standard benefit. seamlessly management. suggesting Phase a iNKT published Our the clinical patients data ARDS results significant XXX in improvement for from that protocols survival a promising role days I/II demonstrates
from This our American the trials, a on respiratory building showing expanded additional Phase we with our Society clinical compelling ATS our access severe findings clinical is in Meeting, or of presented At II the transplant Annual from distress. program, immunocompromised efficacy Thoracic recent data. and patients COVID-XX-induced I ill critically XXX
Following of cytokines, to trial, the and to experienced rapid successful a clinical in patient this in administration reduction dosing our a rapid XXX, leading hospital. the discharge similar single inflammatory excavation from
XXX respiratory With nearly important XX% The acute to XXX,XXX therapy care eliminating unmet. individuals with alone an of to burden health our of is key by distress, the those XX% the is States respiratory conditions, affected system in potential United contribute severe annually to patients on or results promising mitigating companies ARDS, of and data regulatory that this challenging [ disease bona therapies ] group in few in and the one could be promising most MiNK XXX health our of implications. a field. as candidates advancing suggests this select has setting, the and broader care early Therapeutics a about
launch graft to a cell allogeneic our patients going transplantation. transitioning with I'm excited feel I steroid-refractory in hematopoietic upcoming immune and improved of announce to setting building for another to disease versus and disease we on promising a outcomes be optimization We're in and for significant and findings stem Phase host trial therapy. Now the priority the acute us that is
marrow U.S. iNKT treatment transplants, effective broadening the and leading sub in donor applications will step patients in of represents limited Our bone have attack investigator-sponsored recipient's options. cells trial Europe, a GvHD and is our potentially where centers, hematology life-threatening regions include platform one body. where immune and critical in X the the in complication a therapeutic serious one of
to preserving severity the effect. reduce versus designed of immune Our modulate iNKT cell while and GvHD disease tumor therapy this is graft aiming to the or incidence response,
We're in readiness influence. early XXXX. with sites engraftment, year improved such also the with to recurrence, important may design activate other to which late to study trial as disease and positively or institutions infections and our plans this collaborating explore iNKT very currently first the finalize with partnering investigators endpoints year by The cells dosing
important ongoing ], in of Kettering another is trial internationally initiative in oncology in recognized Phase II gastric Memorial currently Oncology cancer. Chief in of advancing a gastric in program a of our [ leadership second-line we expert cancer. under and Hospital Now underway is Dr. have trial Center Cancer Gastrointestinal This Sloan XXX Elena the She's
the of of next-generation has number XXX settings. which inhibitors, potential checkpoint disease Our and very in study is in shown promising with balstilimab, a botisomab Genesis evaluating responses the combination antitumor
explore offering a to with opportunity cell modality checkpoint critical new for treatment iNKT therapy of a advanced with represents cancer. advanced collaboration gastric powerful the synergistic benefit potentially Our inhibitors, patients
condition signals mentioned historically already activity the between a Enrollment as therapeutic months X patients tolerability majority clinical have This these where is of patients months X and clinical optimistic with follow-up this the of some and exceeding and to in exciting options, benefit are We're trial I semblance XX demonstrated these now and very and survival underway, combinations. earlier, of first limited in the patients. population. is activity, X of in cohort of balance the of of very showing actively about
very data We expect to oncology early major at in conference see this a XXXX. or presentation year
that and Dijk, to review are Chief earlier stage van Now he'll Marc? I over our will programs turn Dr. Officer, Scientific advancing. the Marc call our
